Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 14, 2025

Eisai and Biogen report Leqembi’s MHRA approval for Alzheimer’s

Eisai and Biogen have announced the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) approval for Leqembi (lecanemab) for intravenous (IV) maintenance dosing once every four weeks to treat early Alzheimer’s disease.

Continue
Leqembi for IV maintenance dosing is approved once every four weeks to treat early Alzheimer’s. Credit: Robina Weermeijer on Unsplash
November 13, 2025

BostonGene and Kyoto University link on oesophageal cancer drug

The research expands upon the investigator-initiated Phase II Nobel clinical study. Credit: National Cancer Institute on Unsplash.
November 12, 2025

March Bio’s MB‑105 gains FDA RMAT for CD5+ T‑cell lymphoma

March Bio intends to investigate commercial and clinical development opportunities outside the US for the therapy. Credit: CDC on Unsplash

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Novartis opens California site for RLT manufacturing
  2. SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases
  3. Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz
  4. Leukogene Therapeutics gains FDA ODD status for M2T-CD33
  5. AmacaThera and Pacira sign agreement for AMT-143

PRESS RELEASES

Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities
Gerresheimer at CPHI Frankfurt 2025
Gerresheimer at CPHI Frankfurt 2025
Pharmaceutical Business Review
LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds

Suppliers

Whitepapers

Pharmaceutical Business Review
EVERIC® Pure – The Safe Option Right from the Start
Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme